

Tatsuya Atsumi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/314754/publications.pdf>

Version: 2024-02-01

282
papers

6,080
citations

81743

39
h-index

102304

66
g-index

290
all docs

290
docs citations

290
times ranked

5497
citing authors

#	ARTICLE	IF	CITATIONS
1	Number needed to treat and cost per responder of Janus kinase inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis in Japan. <i>Modern Rheumatology</i> , 2023, 33, 54-63.	0.9	1
2	Lipid Droplet Protein PLIN1 Regulates Inflammatory Polarity in Human Macrophages and is Involved in Atherosclerotic Plaque Development by Promoting Stable Lipid Storage. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, 30, 170-181.	0.9	6
3	Characteristics of Patients With Antiphospholipid Antibody Positivity in the <sc>APS ACTION</sc> International Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2022, 74, 324-335.	1.5	39
4	Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). <i>Modern Rheumatology</i> , 2022, 32, 59-67.	0.9	6
5	Glucokinase activation leads to an unsustained hypoglycaemic effect with hepatic triglyceride accumulation in <sc>i>db/db</i></sc> mice. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 391-401.	2.2	6
6	Impact of low-starch high-fiber pasta on postprandial blood glucose. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 487-493.	1.1	3
7	Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?. <i>Endocrine Journal</i> , 2022, 69, 495-509.	0.7	2
8	Cost-Effectiveness Analysis of Etanercept 25 mg Maintenance Therapy After Treatment with Etanercept 50 mg for Moderate Rheumatoid Arthritis in the PRESERVE Trial in Japan. <i>Value in Health Regional Issues</i> , 2022, 28, 105-111.	0.5	2
9	Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). <i>Modern Rheumatology</i> , 2022, 32, 263-272.	0.9	10
10	Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillance. <i>Modern Rheumatology</i> , 2022, 32, 508-516.	0.9	2
11	Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). <i>Modern Rheumatology</i> , 2022, 32, 273-283.	0.9	3
12	Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-9.	1.0	5
13	Class 3 phosphoinositide 3-kinase promotes hepatic glucocorticoid receptor stability and transcriptional activity. <i>Acta Physiologica</i> , 2022, , e13793.	1.8	4
14	Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study. <i>Rheumatology</i> , 2022, 61, 4273-4285.	0.9	3
15	Lymphocytic panhypophysitis and anti-rabphilin-3A antibody with pulmonary sarcoidosis. <i>Pituitary</i> , 2022, 25, 321.	1.6	2
16	Posterior scleritis with anti-neutrophil cytoplasmic antibody-associated vasculitis utilizing rituximab therapy to maintain remission: A case report. <i>American Journal of Ophthalmology Case Reports</i> , 2022, 25, 101333.	0.4	5
17	Lysosomal exocytosis of HSP70 stimulates monocytic BMP6 expression in Sjögren's syndrome. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	9
18	Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial. <i>Rheumatology</i> , 2022, , .	0.9	0

#	ARTICLE	IF	CITATIONS
19	Soluble Interleukin-2 Receptor Predicts Treatment Outcome in Patients With Autoimmune Tubulointerstitial Nephritis. A Preliminary Study. <i>Frontiers in Medicine</i> , 2022, 9, 827388.	1.2	1
20	Axial Spondyloarthritis in Diffuse Idiopathic Skeletal Hyperostosis. <i>Journal of Rheumatology</i> , 2022, , jrheum.220082.	1.0	0
21	Disease activity as a risk factor for venous thromboembolism in rheumatoid arthritis analysed using time-averaged DAS28CRP: a nested caseâ€“control study. <i>Rheumatology International</i> , 2022, 42, 1939-1946.	1.5	9
22	Direct visualization of glucagonâ€“like peptideâ€“1 secretion by fluorescent fusion proteins. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1134-1139.	1.1	1
23	Aberrant functional connectivity between anterior cingulate cortex and left insula in association with therapeutic response to biologics in inflammatory arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 151994.	1.6	5
24	Glycogen synthase kinase 3 β /CCR6 α -positive bone marrow cells correlate with disease activity in multicentric Castleman diseaseâ€“TAFRO. <i>British Journal of Haematology</i> , 2022, 196, 1194-1204.	1.2	0
25	P192â€“Efficacy of filgotinib in rheumatoid arthritis by age, body weight, body mass index: post hoc subgroup analysis of two phase 3 trials. <i>Rheumatology</i> , 2022, 61, .	0.9	0
26	MO218: Anca-Associated Vasculitis After SARS-COV-2 Vaccination in a Patient With HLA-DRB1*09: 01 ALLELE: A Case Report and Literature Review. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	2
27	Diabetic Chorea. <i>Journal of General Internal Medicine</i> , 2022, , .	1.3	0
28	Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study). <i>BMJ Open</i> , 2022, 12, e056885.	0.8	2
29	Reversible Diffuse Bronchial Wall Thickening. <i>Internal Medicine</i> , 2022, , .	0.3	0
30	Clinical impact of urinary CD11b and CD163 on the renal outcomes of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1452-1463.	0.4	5
31	Favorable effect of sodiumâ€“glucose cotransporterâ€“2 inhibitor, dapagliflozin, on nonâ€“alcoholic fatty liver disease compared with pioglitazone. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1272-1277.	1.1	28
32	Inverse correlation between serum highâ€“molecularâ€“weight adiponectin and proinsulin level in a Japanese population: The Dynamics of Lifestyle and Neighborhood Community on Health Study. <i>Journal of Diabetes Investigation</i> , 2021, 12, 63-66.	1.1	2
33	Sodiumâ€“glucose cotransporterâ€“2 inhibitors reduce dayâ€“toâ€“day glucose variability in patients with typeâ€“1 diabetes. <i>Journal of Diabetes Investigation</i> , 2021, 12, 176-183.	1.1	8
34	Impaired insulin secretion predicting unstable glycemic variability and time below range in typeâ€“2 diabetes patients regardless of glycated hemoglobin or diabetes treatment. <i>Journal of Diabetes Investigation</i> , 2021, 12, 738-746.	1.1	10
35	Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. <i>Modern Rheumatology</i> , 2021, 31, 534-542.	0.9	6
36	The association between SLC16A11 haplotype and lipid metabolism in Japanese patients with type 2 diabetes. <i>Drug Metabolism and Pharmacokinetics</i> , 2021, 37, 100376.	1.1	2

#	ARTICLE	IF	CITATIONS
37	Combination of alcohol and glucose consumption as a risk to induce reactive hypoglycemia. <i>Journal of Diabetes Investigation</i> , 2021, 12, 651-657.	1.1	6
38	Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1395-1399.	1.1	1
39	Vascular endothelial growth factor (VEGF)-A and VEGF-A ¹⁶⁵ are associated with time to remission of granulomatosis with polyangiitis in a nationwide Japanese prospective cohort study. <i>Annals of Clinical Biochemistry</i> , 2021, 58, 86-94.	0.8	1
40	COVID-19 pandemic in Japan. <i>Rheumatology International</i> , 2021, 41, 1-5.	1.5	51
41	Efficacy and safety of sodium RISedronate for glucocorticoid-induced Osteoporosis with rheumatoid arthritis (RISOTTO study): A multicentre, double-blind, randomized, placebo-controlled trial. <i>Modern Rheumatology</i> , 2021, 31, 593-599.	0.9	8
42	How should rheumatologists manage glucocorticoid-induced hyperglycemia?. <i>Modern Rheumatology</i> , 2021, 31, 519-528.	0.9	8
43	Morbidity and mortality in antiphospholipid syndrome based on cluster analysis: a 10-year longitudinal cohort study. <i>Rheumatology</i> , 2021, 60, 1331-1337.	0.9	17
44	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021, 48, 541-547.	1.0	19
45	Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The Tj ETQq1 1 0.784314 rgBT /Överlock	1.2	14
46	Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia. <i>Endocrine Journal</i> , 2021, 68, 477-484.	0.7	15
47	Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 727-738.	0.5	76
48	Silent pituitary adenoma and metabolic disorders: obesity, abnormal glucose tolerance, hypertension and dyslipidemia. <i>Endocrine Journal</i> , 2021, 68, 195-200.	0.7	4
49	Glucokinase Inactivation Paradoxically Ameliorates Glucose Intolerance by Increasing β -Cell Mass in db/db Mice. <i>Diabetes</i> , 2021, 70, 917-931.	0.3	17
50	Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1417-1424.	1.1	2
51	Lysosome-associated membrane protein 3 misexpression in salivary glands induces a Sjögren's syndrome-like phenotype in mice. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1031-1039.	0.5	16
52	Exploratory classification of clinical phenotypes in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis using cluster analysis. <i>Scientific Reports</i> , 2021, 11, 5223.	1.6	5
53	Glucokinase is required for high-starch diet-induced β -cell mass expansion in mice. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1545-1554.	1.1	3
54	Severe infection including disseminated herpes zoster triggered by subclinical Cushing's disease: a case report. <i>BMC Endocrine Disorders</i> , 2021, 21, 84.	0.9	2

#	ARTICLE	IF	CITATIONS
55	Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring. <i>Scientific Reports</i> , 2021, 11, 9057.	1.6	7
56	The association between hypoglycemia and glycemic variability in elderly patients with type 2 diabetes: a prospective observational study. <i>Diabetology and Metabolic Syndrome</i> , 2021, 13, 37.	1.2	4
57	Novel mutation in the ALPL gene with a dominant negative effect in a Japanese family. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 804-809.	1.3	1
58	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. <i>Current Rheumatology Reports</i> , 2021, 23, 45.	2.1	9
59	MO244CD47 BLOCKADE AMELIORATES AUTOIMMUNE VASCULITIS VIA THE EFFEROCYTOSIS OF NEUTROPHIL EXTRACELLULAR TRAPS*. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
60	Dipeptidyl peptidase-4 inhibitor might exacerbate Graves' disease: A multicenter observational case-control study. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1978-1982.	1.1	5
61	The role of antirheumatics in patients with COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e447-e459.	2.2	36
62	Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor. <i>Internal Medicine</i> , 2021, 60, 2375-2383.	0.3	1
63	Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study). <i>Diabetes Research and Clinical Practice</i> , 2021, 180, 109069.	1.1	4
64	False hypercortisolemia due to abnormal albumin-cortisol binding in a patient with familial dysalbuminemic hyperthyroxinemia. <i>Thyroid</i> , 2021, , .	2.4	0
65	Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository. <i>Advances in Rheumatology</i> , 2021, 61, 64.	0.8	0
66	Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor. <i>Medicine (United States)</i> , 2021, 100, e27895.	0.4	6
67	The assessment of left heart disease in patients with systemic sclerosis and pulmonary hypertension. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 103-110.	0.4	0
68	Prediction of the intolerance or non-responder to Janus kinase inhibitors in patients with rheumatoid arthritis: a preliminary retrospective study with integrative cluster analysis. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
69	The assessment of left heart disease in patients with systemic sclerosis and pulmonary hypertension. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 103-110.	0.4	0
70	Comparison of administration of single- and triple-course steroid pulse therapy combined with tonsillectomy for immunoglobulin A nephropathy. <i>Medicine (United States)</i> , 2021, 100, e27778.	0.4	0
71	Potential therapeutics for antiphospholipid antibody associated thrombocytopenia: A systematic review and meta-analysis. <i>Modern Rheumatology</i> , 2020, 30, 116-124.	0.9	3
72	Safety and tolerability of sifalimumab, an anti-interferon- γ monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. <i>Modern Rheumatology</i> , 2020, 30, 93-100.	0.9	23

#	ARTICLE	IF	CITATIONS
73	Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab: A pilot study. <i>Modern Rheumatology</i> , 2020, 30, 276-281.	0.9	9
74	The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method. <i>Modern Rheumatology</i> , 2020, 30, 525-531.	0.9	6
75	Impact of Weekly Teriparatide on the Bone and Mineral Metabolism in Hemodialysis Patients With Relatively Low Serum Parathyroid Hormone: A Pilot Study. <i>Therapeutic Apheresis and Dialysis</i> , 2020, 24, 146-153.	0.4	22
76	Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A <i>post hoc</i> analysis of the SURPRISE study. <i>Modern Rheumatology</i> , 2020, 30, 442-449.	0.9	2
77	Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. <i>Rheumatology</i> , 2020, 59, 1084-1093.	0.9	27
78	Case with long-standing gout showing various ultrasonographic features caused by monosodium urate monohydrate crystal deposition. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 110-115.	0.3	3
79	Proinsulin is sensitive to reflect glucose intolerance. <i>Journal of Diabetes Investigation</i> , 2020, 11, 75-79.	1.1	8
80	Pre-conception status, obstetric outcome and use of medications during pregnancy of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) in Japan: Multi-center retrospective descriptive study. <i>Modern Rheumatology</i> , 2020, 30, 852-861.	0.9	20
81	Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts. <i>Autophagy</i> , 2020, 16, 946-955.	4.3	26
82	First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 387-392.	0.5	17
83	Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study). <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 458-462.	2.2	12
84	Recombinant thrombomodulin ameliorates autoimmune vasculitis via immune response regulation and tissue injury protection. <i>Journal of Autoimmunity</i> , 2020, 108, 102390.	3.0	14
85	Relationships between plasma lactate, plasma alanine, genetic variations in lactate transporters and type 2 diabetes in the Japanese population. <i>Drug Metabolism and Pharmacokinetics</i> , 2020, 35, 131-138.	1.1	10
86	Thrombomodulin as a Physiological Modulator of Intravascular Injury. <i>Frontiers in Immunology</i> , 2020, 11, 575890.	2.2	40
87	Correlation between serum proinsulin levels and fatty liver: The Dynamics of Lifestyle and Neighborhood Community on Health Study. <i>Journal of Diabetes Investigation</i> , 2020, 11, 964-970.	1.1	4
88	Low C4 as a risk factor for severe neuropsychiatric flare in patients with systemic lupus erythematosus. <i>Lupus</i> , 2020, 29, 1238-1247.	0.8	8
89	SAT-177 Relationship Between Visceral Fat and the Position of Adrenal Glands in Cranial-Caudal Direction in Patients with Primary Aldosteronism. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
90	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020, 29, 1353-1363.	0.8	28

#	ARTICLE	IF	CITATIONS
91	Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study. <i>BMJ Open</i> , 2020, 10, e034883.	0.8	2
92	Intrafamilial phenotypic distinction of hypophosphatasia with identical tissue nonspecific alkaline phosphatase gene mutation: a family report. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 903-907.	1.3	2
93	Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension: current recommendations and recent advances. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 993-1004.	1.3	7
94	LAMP3 induces apoptosis and autoantigen release in Sjögren's syndrome patients. <i>Scientific Reports</i> , 2020, 10, 15169.	1.6	34
95	P0340CYPD DEFICIENCY AMELIORATES AUTOIMMUNE VASCULITIS IN MOUSE MODEL VIA THE INHIBITION OF PROGRAMMED NECROSIS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
96	Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis. <i>Journal of Diabetes Investigation</i> , 2020, 12, 1293-1300.	1.1	3
97	A comparative study of PF06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 876-881.	0.9	7
98	Non-tuberculosis Mycobacterium Tenosynovitis with Rice Bodies in a Patient with Systemic Lupus Erythematosus. <i>Internal Medicine</i> , 2020, 59, 2317-2320.	0.3	6
99	The risk factors for hepatic steatosis in patients with primary aldosteronism. <i>Endocrine Journal</i> , 2020, 67, 623-629.	0.7	5
100	Antiresorptive agents-related osteonecrosis of the jaw (ARONJ) in rheumatoid arthritis. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 739-741.	1.3	3
101	Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 581-588.	1.3	11
102	Myofascia-dominant involvement on whole-body MRI as a risk factor for rapidly progressive interstitial lung disease in dermatomyositis. <i>Rheumatology</i> , 2020, 59, 1734-1742.	0.9	13
103	Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. <i>Rheumatology</i> , 2020, 59, 2427-2434.	0.9	81
104	MicroRNA-9 ameliorates destructive arthritis through down-regulation of NF- κ B1-RANKL pathway in fibroblast-like synoviocytes. <i>Clinical Immunology</i> , 2020, 212, 108348.	1.4	23
105	Convolutional neural network for classification of two-dimensional array images generated from clinical information may support diagnosis of rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 5648.	1.6	15
106	Effects of <i>Palmaria palmata</i> on lipid metabolism and glycemic control in participants with hypercholesterolemia in a randomized double-blind placebo-controlled trial. <i>Phytotherapy Research</i> , 2020, 34, 2303-2312.	2.8	6
107	Protective Role of Optineurin Against Joint Destruction in Rheumatoid Arthritis Synovial Fibroblasts. <i>Arthritis and Rheumatology</i> , 2020, 72, 1493-1504.	2.9	10
108	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 618-625.	0.5	71

#	ARTICLE	IF	CITATIONS
109	Increased urinary exosomal SYT17 levels in chronic active antibody-mediated rejection after kidney transplantation via the IL-6 amplifier. <i>International Immunology</i> , 2020, 32, 653-662.	1.8	21
110	Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 532.	1.8	6
111	MON-483 Familial Dysalbuminemic Hyperthyroxinemia with False Hypercortisolemia. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
112	Fluvastatin prevents the development of arthritis in env-pX rats via up-regulation of Rho GTPase-activating protein 12. <i>Experimental and Molecular Pathology</i> , 2020, 115, 104454.	0.9	0
113	MON-465 Novel Thyroid Hormone \hat{I}^2 Mutation L266s Causes Atrial Fibrillation & Cerebral Infarction. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
114	SAT-271 Block and Replace Therapy Successfully Improved Symptoms in Recurrent Cyclic Cushing's Disease. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
115	SAT-282 Hypothalamic Pituitary Adrenal Axis Hyperactivity in Db/db Mice. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
116	Calcineurin inhibitors for adult-onset Still's disease: a multicentre retrospective cohort study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 127, 11-16.	0.4	0
117	Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial. <i>Journal of Diabetes Investigation</i> , 2019, 10, 699-705.	1.1	26
118	Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea. <i>Journal of Diabetes Investigation</i> , 2019, 10, 367-374.	1.1	15
119	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2069-2080.	1.9	9
120	Right ventricular dimension index by cardiac magnetic resonance for prognostication in connective tissue diseases and pulmonary hypertension. <i>Rheumatology</i> , 2019, 59, 622-633.	0.9	2
121	Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis. <i>Rheumatology International</i> , 2019, 39, 1883-1887.	1.5	5
122	FP061 RECOMBINANT THROMBOMODULIN AMELIORATES VASCULITIS VIA THE INHIBITION OF NEUTROPHIL EXTRACELLULAR TRAPS. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
123	The Pathogenicity of BPI-ANCA in a Patient With Systemic Vasculitis. <i>Frontiers in Immunology</i> , 2019, 10, 1334.	2.2	6
124	SaO001 THE EFFECT OF L-TYPE AMINO ACID TRANSPORTER 1 IN THE CYST FORMATION OF MODEL MICE FOR POLYCYSTIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
125	SP004 LONG-TERM TREATMENT OF TOLVAPTAN FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A SINGLE CENTRE RETROSPECTIVE COHORT STUDY. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
126	SP175 Longitudinal outcome of a restrictive therapeutic algorithm in Japanese patients with idiopathic membranous nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0

#	ARTICLE	IF	CITATIONS
127	FP125A ROLE OF SOLUBLE INTERLEUKIN-2 RECEPTOR LEVELS IN THE PREDICTION OF STEROID RESPONSE IN PATIENTS WITH TUBULOINTERSTITIAL NEPHRITIS. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
128	FP453WEEKLY TERIPARATIDE AGENT POTENTIATES BONE MINERAL TURN OVER IN HEMODIALYSIS PATIENTS WITH LOW PARATHYROID HORMONE (PTH) LEVELS: A PROSPECTIVE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
129	Formation and Disordered Degradation of Neutrophil Extracellular Traps in Necrotizing Lesions of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>American Journal of Pathology</i> , 2019, 189, 839-846.	1.9	24
130	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , 2019, 175, 32-36.	0.8	13
131	Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation. <i>Endocrine Journal</i> , 2019, 66, 937-941.	0.7	15
132	Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice. <i>Metabolism: Clinical and Experimental</i> , 2019, 98, 27-36.	1.5	28
133	Detection of Increased Vascular Signal in Arthritis-Prone Rats Without Joint Swelling Using Superb Microvascular Imaging Ultrasonography. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 2086-2093.	0.7	4
134	Quantitative power Doppler signal assessment in the subchondral bone region of the metacarpophalangeal joint is an effective predictor of radiographic progression in the hand of rheumatoid arthritis: a pilot study. <i>Rheumatology International</i> , 2019, 39, 1413-1421.	1.5	1
135	Has lupus anticoagulant testing had its day?. <i>Nature Reviews Rheumatology</i> , 2019, 15, 324-325.	3.5	1
136	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 464-468.	1.6	79
137	Disseminated subcutaneous nodules and destructive polyarthritis. <i>BMJ: British Medical Journal</i> , 2019, 365, 11344.	2.4	2
138	The presence of anti-neutrophil extracellular trap antibody in patients with microscopic polyangiitis. <i>Rheumatology</i> , 2019, 58, 1293-1298.	0.9	14
139	Rheumatology practice in Japan: challenges and opportunities. <i>Rheumatology International</i> , 2019, 39, 1499-1505.	1.5	2
140	Breakdown of Autonomously Functioning Thyroid Nodule Accompanied by Acromegaly After Octreotide Treatment. <i>Frontiers in Endocrinology</i> , 2019, 10, 131.	1.5	4
141	Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1134-1143.	1.9	27
142	Case of fulminant type 1 diabetes induced by the anti-programmed death-1 ligand 1 antibody, avelumab. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1385-1387.	1.1	10
143	FRI099...PREDICTIVE FACTORS FOR REMISSION ACHIEVEMENT BY TOCILIZUMAB MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER INADEQUATE RESPONSE TO METHOTREXATE: A POST HOC ANALYSIS OF THE SURPRISE STUDY. , 2019, , .		0
144	Flow cytometric identification and cell-line establishment of macrophages in naked mole-rats. <i>Scientific Reports</i> , 2019, 9, 17981.	1.6	7

#	ARTICLE	IF	CITATIONS
145	Citelman's syndrome with hyperphosphatemia, effectively responding to single oral magnesium oxide administration. <i>Medicine (United States)</i> , 2019, 98, e16408.	0.4	2
146	Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2019, 10, 429-438.	1.1	7
147	Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 574-582.	0.9	40
148	Clinical significance of anti- α -DNA /N α -methyl- α -aspartate receptor 2 antibodies in de novo and post-steroid cases with neuropsychiatric systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 443-448.	0.9	4
149	Clinical profiles and risk assessment in patients with antiphospholipid antibodies. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 73-81.	1.3	10
150	Effect of switching from pioglitazone to the sodium glucose co-transporter 2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 710-714.	2.2	12
151	Antiphospholipid score is a novel risk factor for idiopathic osteonecrosis of the femoral head in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 645-649.	0.9	19
152	Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome. <i>Rheumatology</i> , 2019, 58, 969-974.	0.9	24
153	Histopathological classification of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a nationwide Japanese prospective 2-year follow-up cohort study. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 387-394.	0.7	9
154	Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study. <i>Modern Rheumatology</i> , 2019, 29, 314-323.	0.9	34
155	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and International Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019, 71, 134-141.	1.5	37
156	SAT-002 Measurement of Visceral Fat Using Computed Tomography in Two Subtypes of Primary Aldosteronism. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
157	Alternative pathway activation due to low level of complement factor H in primary antiphospholipid syndrome. <i>Thrombosis Research</i> , 2018, 164, 63-68.	0.8	7
158	The role of genetics and epigenetics in rheumatic diseases: are they really a target to be aimed at?. <i>Rheumatology International</i> , 2018, 38, 1333-1338.	1.5	15
159	Serum adiponectin and insulin secretion: A direct or inverse association?. <i>Journal of Diabetes Investigation</i> , 2018, 9, 1106-1109.	1.1	23
160	Antiphospholipid syndrome, "the best prophet of the future". <i>Modern Rheumatology</i> , 2018, 28, 409-416.	0.9	17
161	Splicing variant of <i>WDFY4</i> augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 602-611.	0.5	51
162	Pulmonary arterial hypertension associated with connective tissue diseases: A review focusing on distinctive clinical aspects. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12876.	1.7	23

#	ARTICLE	IF	CITATIONS
163	Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting. <i>Modern Rheumatology</i> , 2018, 28, 780-788.	0.9	14
164	Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: Long-term follow-up on a phase II trial and treatment-related fatal cardiomyopathy. <i>Modern Rheumatology</i> , 2018, 28, 879-884.	0.9	14
165	Effect of combined treatment with bisphosphonate and vitamin D on atherosclerosis in patients with systemic lupus erythematosus: a propensity score-based analysis. <i>Arthritis Research and Therapy</i> , 2018, 20, 72.	1.6	7
166	Composite assessment of power Doppler ultrasonography and MRI in rheumatoid arthritis: a pilot study of predictive value in radiographic progression after one year. <i>British Journal of Radiology</i> , 2018, 91, 20170748.	1.0	4
167	Active synovitis in the presence of osteitis predicts residual synovitis in patients with rheumatoid arthritis with a clinical response to treatment. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1809-1814.	0.9	0
168	First-Line, Non-Criteria Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti-β ₂ -Glycoprotein I Domain I and Anti-Phosphatidylserine/Prothrombin Complex Antibodies Tests. <i>Arthritis Care and Research</i> , 2018, 70, 627-634.	1.5	52
169	Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder. <i>Arthritis and Rheumatology</i> , 2018, 70, 277-286.	2.9	45
170	Clinical feature and anti-phospholipid antibody profiles of pregnancy failure in young women with antiphospholipid antibody syndrome treated with conventional therapy. <i>Modern Rheumatology</i> , 2018, 28, 670-675.	0.9	6
171	Prodromal signs and symptoms of serious infections with tocilizumab treatment for rheumatoid arthritis: Text mining of the Japanese postmarketing adverse event-reporting database. <i>Modern Rheumatology</i> , 2018, 28, 435-443.	0.9	7
172	Clinical significance of plasma presepsin levels in patients with systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2018, 28, 865-871.	0.9	12
173	Interferon-inducible Mx1 protein is highly expressed in renal tissues from treatment-naïve lupus nephritis, but not in those under immunosuppressive treatment. <i>Modern Rheumatology</i> , 2018, 28, 661-669.	0.9	16
174	Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). <i>Modern Rheumatology</i> , 2018, 28, 642-648.	0.9	16
175	Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials. <i>Modern Rheumatology</i> , 2018, 28, 583-591.	0.9	36
176	SP027 EFFICACY OF TOLVAPTAN ON AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PATIENTS IN LATE STAGE CKD. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i355-i356.	0.4	1
177	Kasabach-Merritt phenomenon with concurrent appearance of antiphospholipid antibodies in a patient with giant liver haemangioma. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky047.	0.3	0
178	FO038 EFFECTS OF RECOMBINANT THROMBOMODULIN ON EXPERIMENTAL AUTOIMMUNE VASCULITIS VIA THE INHIBITION OF NEUTROPHIL EXTRACELLULAR TRAPS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i34-i34.	0.4	0
179	Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes—Randomized controlled study. <i>Endocrine Journal</i> , 2018, 65, 141-150.	0.7	7
180	Detection of Autoreactive Type II NKT Cells: A Pilot Study of Comparison Between Healthy Individuals and Patients with Vasculitis. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 1157-1164.	1.1	3

#	ARTICLE	IF	CITATIONS
181	Relationship Between Visceral Fat and Plasma Aldosterone Concentration in Patients With Primary Aldosteronism. <i>Journal of the Endocrine Society</i> , 2018, 2, 1236-1245.	0.1	20
182	Potential Importance of a Histopathological Analysis in Thyroidal Diseases with High Serum IgG4 Levels. <i>Internal Medicine</i> , 2018, 57, 453-453.	0.3	1
183	Systemic lupus erythematosus: nothing stale her infinite variety. <i>Modern Rheumatology</i> , 2018, 28, 758-765.	0.9	27
184	Ectopic RASGRP2 (CalDAG-GEFI) expression in rheumatoid synovium contributes to the development of destructive arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1765-1772.	0.5	21
185	Impact of Glucose Loading on Variations in CD4+ and CD8+ T Cells in Japanese Participants with or without Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2018, 9, 81.	1.5	14
186	Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages. <i>Scientific Reports</i> , 2018, 8, 6864.	1.6	22
187	Successful treatment of tocilizumab-resistant large vessel pulmonary arteritis with infliximab. <i>Immunological Medicine</i> , 2018, 41, 39-42.	1.4	5
188	The data of change in macrophage gene expression which induced by perilipin 1 overexpression. <i>Data in Brief</i> , 2018, 19, 179-182.	0.5	1
189	Comment on "Elevation of Serum Carcinoembryonic Antigen Concentration Caused by Everolimus-Induced Lung Injury: A Case Report". <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2018, 24, 165-166.	0.3	0
190	Efficient detection of pulmonary arterial hypertension using serum haptoglobin level and cardiac MRI in patients with connective tissue diseases: a pilot study. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 345-346.	0.4	1
191	Laboratory Markers With Clinical Significance in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 47-69.	0.1	0
192	Insulin-Induced Distant Site Lipoatrophy. <i>Diabetes Care</i> , 2017, 40, e67-e68.	4.3	4
193	Transethnic meta-analysis identifies <i>GSDMA</i> and <i>PRDM1</i> as susceptibility genes to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1150-1158.	0.5	77
194	Power Doppler signal calibration in the finger joint between two models of ultrasound machine: a pilot study using a phantom and joints in patients with rheumatoid arthritis. <i>Acta Radiologica</i> , 2017, 58, 1238-1244.	0.5	6
195	How to Identify High-Risk APS Patients: Clinical Utility and Predictive Values of Validated Scores. <i>Current Rheumatology Reports</i> , 2017, 19, 51.	2.1	20
196	Bi-ventricular interplay in patients with systemic sclerosis-associated pulmonary arterial hypertension: Detection by cardiac magnetic resonance. <i>Modern Rheumatology</i> , 2017, 27, 481-488.	0.9	5
197	Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide. <i>Internal Medicine</i> , 2017, 56, 445-448.	0.3	8
198	A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 54.	1.2	35

#	ARTICLE	IF	CITATIONS
199	Diversity of borderline pulmonary arterial pressure associated with systemic sclerosis: 3 case series. <i>Modern Rheumatology Case Reports</i> , 2017, 1, 9-14.	0.3	3
200	Disease and Risk Measurement Criteria in Antiphospholipid Syndrome. , 2017, , 189-199.		0
201	SPO2EFFECT OF TOLVAPTAN ON A BODY WATER BALANCE IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i93-i93.	0.4	0
202	Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1917-1923.	0.5	81
203	Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data. <i>Clinical Therapeutics</i> , 2016, 38, 1359-1375.e1.	1.1	19
204	Differentiating biosimilarity and comparability in biotherapeutics. <i>Clinical Rheumatology</i> , 2016, 35, 2877-2886.	1.0	30
205	Significance of fully automated tests for the diagnosis of antiphospholipid syndrome. <i>Thrombosis Research</i> , 2016, 146, 1-6.	0.8	23
206	Autoantibodies against a complement component 1 q subcomponent contribute to complement activation and recurrent thrombosis/pregnancy morbidity in anti-phospholipid syndrome. <i>Rheumatology</i> , 2016, 55, 1403-1411.	0.9	23
207	Accurate quantitative assessment of synovitis in rheumatoid arthritis using pixel-by-pixel, time-â€“intensity curve shape analysis. <i>British Journal of Radiology</i> , 2016, 89, 20151000.	1.0	4
208	Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention. <i>Rheumatology International</i> , 2016, 36, 635-641.	1.5	3
209	Role of apolipoprotein B100 and oxidized low-density lipoprotein in the monocyte tissue factor induction mediated by anti-Î²2 glycoprotein I antibodies. <i>Lupus</i> , 2016, 25, 1288-1298.	0.8	7
210	Post-steroid neuropsychiatric manifestations are significantly more frequent in SLE compared with other systemic autoimmune diseases and predict better prognosis compared with de novo neuropsychiatric SLE. <i>Autoimmunity Reviews</i> , 2016, 15, 786-794.	2.5	23
211	Ribophorin II is involved in the tissue factor expression mediated by phosphatidylserine-dependent antiprothrombin antibody on monocytes. <i>Rheumatology</i> , 2016, 55, 1117-1126.	0.9	2
212	Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. <i>Modern Rheumatology</i> , 2016, 26, 730-737.	0.9	39
213	The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 75-83.	0.5	94
214	Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early Diagnosis and Treatment of Osteoporosis in Japan (EDITOR-J) study. <i>Journal of Bone and Mineral Metabolism</i> , 2016, 34, 646-654.	1.3	15
215	Pathogenesis of Antiphospholipid Syndrome. , 2016, , 487-494.		2
216	Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 1354-1362.	1.5	26

#	ARTICLE	IF	CITATIONS
217	Î²2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome. <i>Blood</i> , 2015, 125, 2835-2844.	0.6	61
218	Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan. <i>Modern Rheumatology</i> , 2015, 25, 854-857.	0.9	11
219	The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. <i>Rheumatology</i> , 2015, 54, 39-44.	0.9	104
220	Structural deterioration of finger joints with ultrasonographic synovitis in rheumatoid arthritis patients with clinical low disease activity. <i>Rheumatology</i> , 2014, 53, 1608-1612.	0.9	15
221	Comparative analysis of different enzyme immunoassays for assessment of phosphatidylserine-dependent antiprothrombin antibodies. <i>Rheumatology International</i> , 2014, 34, 1225-1230.	1.5	8
222	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. <i>Autoimmunity Reviews</i> , 2014, 13, 917-930.	2.5	224
223	A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology. <i>Modern Rheumatology</i> , 2013, 23, 297-303.	0.9	13
224	Phospholipid scramblase 1 expression is enhanced in patients with antiphospholipid syndrome. <i>Modern Rheumatology</i> , 2013, 23, 81-88.	0.9	12
225	Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs. <i>Modern Rheumatology</i> , 2013, 23, 284-296.	0.9	17
226	Essential role of the p38 mitogen-activated protein kinase pathway in tissue factor gene expression mediated by the phosphatidylserine-dependent antiprothrombin antibody. <i>Rheumatology</i> , 2013, 52, 1775-1784.	0.9	25
227	Phospholipid scramblase 1 expression is enhanced in patients with antiphospholipid syndrome. <i>Modern Rheumatology</i> , 2013, 23, 81-88.	0.9	7
228	A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/Î²2 glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies. <i>Modern Rheumatology</i> , 2012, 22, 769-773.	0.9	4
229	Factor XI is a substrate for oxidoreductases: Enhanced activation of reduced FXI and its role in antiphospholipid syndrome thrombosis. <i>Journal of Autoimmunity</i> , 2012, 39, 121-129.	3.0	41
230	Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. <i>Modern Rheumatology</i> , 2012, 22, 394-404.	0.9	77
231	A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/Î²2 glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies. <i>Modern Rheumatology</i> , 2012, 22, 769-773.	0.9	2
232	Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. <i>Arthritis and Rheumatism</i> , 2012, 64, 504-512.	6.7	227
233	Thrombotic microangiopathy due to multiple autoantibodies related to antiphospholipid syndrome. <i>Pediatric Nephrology</i> , 2012, 27, 681-685.	0.9	14
234	Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. <i>Journal of Rheumatology</i> , 2011, 38, 1258-1264.	1.0	141

#	ARTICLE	IF	CITATIONS
235	Plasma gelsolin facilitates interaction between β_2 glycoprotein I and $\alpha_5\beta_1$ integrin. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 141-151.	1.6	25
236	Radiographic prognosis of finger joint damage predicted by early alteration in synovial vascularity in patients with rheumatoid arthritis: Potential utility of power doppler sonography in clinical practice. <i>Arthritis Care and Research</i> , 2011, 63, 1247-1253.	1.5	49
237	Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β_2 glycoprotein I. <i>Arthritis and Rheumatism</i> , 2011, 63, 2774-2782.	6.7	96
238	The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2011, 21, 444-448.	0.9	16
239	Hepatitis B Virus Reactivation by Immunosuppressive Therapy in Patients with Autoimmune Diseases: Risk Analysis in Hepatitis B Surface Antigen-negative Cases. <i>Journal of Rheumatology</i> , 2011, 38, 2209-2214.	1.0	50
240	Change of synovial vascularity in a single finger joint assessed by power doppler sonography correlated with radiographic change in rheumatoid arthritis: Comparative study of a novel quantitative score with a semiquantitative score. <i>Arthritis Care and Research</i> , 2010, 62, 657-663.	1.5	50
241	Antiprothrombin antibody: why do we need more assays?. <i>Lupus</i> , 2010, 19, 436-439.	0.8	37
242	Increased Expression of Phospholipid Scramblase 1 in Monocytes from Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 1639-1645.	1.0	16
243	The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation. <i>Arthritis and Rheumatism</i> , 2009, 60, 2457-2467.	6.7	41
244	Exchange of information in rheumatology between east and west: From Man'yo-shu to the future. <i>Arthritis and Rheumatism</i> , 2008, 58, S140-S142.	6.7	1
245	Antiprothrombin Antibody Testing: Detection and Clinical Utility. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 335-339.	1.5	32
246	Diagnosis of Antiphospholipid syndrome. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2008, 19, 329-332.	0.1	3
247	Etiopathology of the Antiphospholipid Syndrome. , 2008, , 521-535.		0
248	Defective Expression of Ras Guanyl Nucleotide-Releasing Protein 1 in a Subset of Patients with Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2007, 179, 4890-4900.	0.4	64
249	Resurrection of thrombin in the pathophysiology of the antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2007, 56, 393-394.	6.7	6
250	Genetics of Antiphospholipid Syndrome. , 2006, , 521-531.		1
251	Significance of valine/leucine polymorphism of β_2 -glycoprotein I in antiphospholipid syndrome: Increased reactivity of anti- β_2 -glycoprotein I autoantibodies to the valine β_2 -glycoprotein I variant. <i>Arthritis and Rheumatism</i> , 2005, 52, 212-218.	6.7	56
252	Antigenic structures recognized by anti- β_2 -glycoprotein I auto-antibodies. <i>International Immunology</i> , 2005, 17, 1533-1542.	1.8	31

#	ARTICLE	IF	CITATIONS
253	Research around Î²2-glycoprotein I: A major target for antiphospholipid antibodies. <i>Autoimmunity</i> , 2005, 38, 377-381.	1.2	21
254	Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. <i>Lupus</i> , 2005, 14, 499-504.	0.8	77
255	The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-Î²2Glycoprotein I antibodies. <i>International Immunology</i> , 2004, 16, 1633-1641.	1.8	115
256	Antiprothrombin antibodies“are they worth assaying?. <i>Thrombosis Research</i> , 2004, 114, 533-538.	0.8	40
257	Diagnostic value of antiagalactosyl IgG antibodies in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2004, 23, 218-222.	1.0	30
258	Phosphatidylserine-dependent antiprothrombin antibodies are not useful markers for high-risk women with recurrent miscarriages. <i>Fertility and Sterility</i> , 2004, 82, 1440-1442.	0.5	12
259	Nicked Î²-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. <i>Blood</i> , 2004, 103, 3766-3772.	0.6	54
260	IMMUNOLOGY OF ANTI-PHOSPHOLIPID ANTIBODIES AND COFACTORS. , 2004, , 1081-1105.		7
261	Specificities, properties, and clinical significance of antiprothrombin antibodies. <i>Arthritis and Rheumatism</i> , 2003, 48, 886-895.	6.7	65
262	Circulating oxidized LDL forms complexes with Î²2-glycoprotein I: implication as an atherogenic autoantigen. <i>Journal of Lipid Research</i> , 2003, 44, 716-726.	2.0	165
263	Anti-beta2-glycoprotein I antibodies in children with atopic dermatitis. <i>International Immunology</i> , 2002, 14, 823-830.	1.8	66
264	Clinical relevance of antiprothrombin antibodies. <i>Autoimmunity Reviews</i> , 2002, 1, 49-53.	2.5	21
265	Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome. <i>British Journal of Haematology</i> , 2002, 119, 781-788.	1.2	41
266	GENETICS OF ANTIPHOSPHOLIPID SYNDROME. <i>Rheumatic Disease Clinics of North America</i> , 2001, 27, 565-572.	0.8	12
267	An evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of arterial thrombosis in patients with the antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2000, 43, 1655-1656.	6.7	11
268	Association of autoantibodies against the phosphatidylserine“prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. <i>Arthritis and Rheumatism</i> , 2000, 43, 1982-1993.	6.7	299
269	Coagulation and fibrinolytic activities in 2 siblings with Î²2-glycoprotein I deficiency. <i>Blood</i> , 2000, 96, 1594-1595.	0.6	45
270	Proteolytic cleavage of Î²2-glycoprotein I: reduction of antigenicity and the structural relationship. <i>International Immunology</i> , 2000, 12, 1183-1192.	1.8	35

#	ARTICLE	IF	CITATIONS
271	Î²2-glycoprotein I deficiency:. Atherosclerosis, 2000, 152, 337-346.	0.4	77
272	Effects of Î²2-Glycoprotein I and Monoclonal Anticardiolipin Antibodies on Extrinsic Fibrinolysis. Seminars in Thrombosis and Hemostasis, 2000, Volume 26, 085-090.	1.5	32
273	?2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis and Rheumatism, 1999, 42, 167-174.	6.7	58
274	A chimeric antibody with the human ?1 constant region as a putative standard for assays to detect IgG ?2-glycoprotein I-dependent anticardiolipin and anti-?2-glycoprotein I antibodies. Arthritis and Rheumatism, 1999, 42, 2461-2470.	6.7	91
275	Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome. Arthritis and Rheumatism, 1999, 42, 2606-2611.	6.7	35
276	Arterial disease and thrombosis in the antiphospholipid syndrome: A pathogenic role for endothelin 1. Arthritis and Rheumatism, 1998, 41, 800-807.	6.7	124
277	IgG2 restriction of anti-Î²2-glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome: Comment on the article by Sammaritano et al. Arthritis and Rheumatism, 1998, 41, 1513-1514.	6.7	16
278	The Role of the Tissue Factor Pathway in the Hypercoagulable State in Patients with the Antiphospholipid Syndrome. Thrombosis and Haemostasis, 1998, 79, 276-281.	1.8	256
279	Up-Regulated Tissue Factor Expression in Antiphospholipid Syndrome. Thrombosis and Haemostasis, 1997, 77, 222-223.	1.8	32
280	Trigeminal sensory neuropathy in primary Sjogren's syndrome: case reports and review of the literature.. Japanese Journal of Clinical Immunology, 1992, 15, 168-176.	0.0	0
281	A case of systemic lupus erythematosus with pure red cell aplasia responded to steroid pulse therapy.. Japanese Journal of Clinical Immunology, 1991, 14, 639-645.	0.0	0
282	Prediction of the intolerance or non-responder to Janus kinase inhibitors in patients with rheumatoid arthritis: a preliminary retrospective study with integrative cluster analysis. Clinical and Experimental Rheumatology, 0, , .	0.4	3